Company intelligence / Profile preview

IONIQ Sciences

Salt Lake City, Utah, United States

Ownership: Private
Development stage: Other

Overview

The ProLung Test for lung cancer has been designated a Breakthrough Device by the U.S. FDA[5]. External clinical validation results and internal discoveries suggest IONIQ's Electrical Impedance Analytics technology is measuring the body's early warning system to the presence and localities of cancer malignancies[5]. The company initiated an IRB-approved feasibility study on breast cancer at the beginning of 2020[5].

Therapeutic areas: Oncology
Modalities: Device
Industry: Physiological Monitoring

Beyond the preview

Go deeper on IONIQ Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IONIQ Sciences.

Explore the full profile